Chemotherapy and cardiotoxicity

Reviews in Cardiovascular Medicine

Volumn 9, Issue 2, 2008, Pages 75-83

  Broder, Howard ^a   Gottlieb, Roberta A ^b   Lepor, Norman E ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 Fluorouracil; Anthracyclines; Cancer; Cardiotoxicity; Chemotherapy; Trastuzumab

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTHRACYCLINE; ANTIANDROGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM ANTAGONIST; CAPECITABINE; CARBOPLATIN; CARVEDILOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; MITOXANTRONE; NITRATE; PACLITAXEL; RAZOXANE; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

ANDROGEN THERAPY; ANGINA PECTORIS; BRADYCARDIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; COLON METASTASIS; CONGESTIVE HEART FAILURE; CYTOLOGY; DYSPNEA; ELECTROCARDIOGRAM; HEART ARREST; HEART ARRHYTHMIA; HEART EDEMA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG EDEMA; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MORBIDITY; MORTALITY; MYOCARDITIS; MYOPERICARDITIS; NONHUMAN; PERICARDITIS; PROSTATE CANCER; RECTUM METASTASIS; REVIEW; SIDE EFFECT; SINUS TACHYCARDIA; ST SEGMENT ELEVATION; T WAVE; THORAX PAIN; THROMBOEMBOLISM;

AGE OF ONSET; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; DRUG THERAPY; DRUG TOXICITY; FLUOROURACIL; HEART FAILURE, SYSTOLIC; HUMANS; NEOPLASMS; PERICARDITIS; TIME FACTORS;

EID: 48749096703     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Cancer Facts and Figures 2006. American Cancer Society Web site. http://www.cancer. org/docroot/STT/content/STT_1x_Cancer_Facts_Figures_2006.asp. Accessed April 20, 2008.
2. DeMarco A, Gaetani M, Scarpinato B. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969;53:33-37.
3. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
4. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol. 2006;33 (3 suppl):S2-S7.
5. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med. 2004; 351:120-121.
6. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
7. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492-2498.
8. Giantris A, Abdurrahman L, Hinkle A, et al. An-thracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27:53-68.
9. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
10. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 1981;68:1053-1064.
11. Dhalla AK, Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol. 1994;266(4 Pt 2):H1280-H1285.
12. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 1995;91:10-15.
13. Siwik DA, Tzortzis JD, Pimental DR, et al. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res. 1999;85:147-153.
14. Unverferth DV, Fertel RH, Altschuld R, et al. Biochemical measurements of endomyocardial biopsies. Cathet Cardiovasc Diagn. 1981;7:55-64.
15. Nicolay K, Timmers RJ, Spoelstra E, et al. The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes. Biochim Biophys Acta. 1984;778:359-371.
16. Goormaghtigh E, Huart P, Praet M, et al. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem. 1990;35:247-257.
17. Eidenschink AB, Schröter G, Müller-Weihrich S, Stern H. Myocardial high-energy phosphate metabolism is altered after treatment with anthracycline in childhood. Cardiol Young. 2000;10:610-617.
18. Lebrecht D, Kokkori A, Ketelsen UP, et al. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207: 436-444.
19. Lebrecht D, Setzer B, Rohrbach R, Walker UA. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. Nephrol Dial Transplant. 2004;19:329-336.
20. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-776.
21. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA. 2003,100:12313-12318.
22. Martin CM, Meeson AP, Robertson SM, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol. 2004;265:262-275.
23. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004; 95:911-921.
24. Laugwitz KL, Moretti A, Lam J, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433:647-653.
25. Tomlta 5, Ishida M, Nakatani T, et al. Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy. J Heart Lung Transplant. 2004;23:577-584.
26. Hou XW, Son J, Wang Y, et al. Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther. 2006;20:85-91.
27. Civelli M, Cardinale D, Martinoni A, et al. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol. 2006;111:120-126.
28. Rosenthal DS, Braunwald E. Cardiac effects of radiation therapy and chemotherapy. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders Company; 2001:1746-1751.
29. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987,82:1109-1118.
30. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989,118:92-98.
31. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 2006;7:141-146.
32. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20:62-69.
33. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001;87: 1120-1122.
34. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109: 2749-2754.
35. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-167.
36. van Dalen EC, Caron HN, Dickinson H, Kremer L. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2005;CD003917.
37. Schucter LM, Hensley ML, Meropol NJ, Winer EP, for the American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895-2903.
38. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-2481.
39. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258-2262.
40. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-terra observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709.
41. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother. 1994;28:374-378.
42. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10:1795-1801.
43. Kuropkat C, Griem K, Clark J, et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol. 1999;22:466-470.
44. Cianci G, Morelli MF, Cannita K, et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer. 2003;88: 1507-1509.
45. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004-1014.
46. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
47. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995,10:2435-2446.
48. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001,344: 783-792.
49. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
50. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
51. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592-1600.
52. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-1221.
53. Routledge HC, Rea DW, Steeds RP. Monitoring the introduction of new drugs-Herceptin to cardiotoxicity. Clin Med. 2006;6:478-481.
54. Rastogi P. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab(H). Abstract presented at: 43rd Annual Meeting of the American Society for Clinical Oncology; June 1-5, 2007; Chicago, IL.
55. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-7826.
56. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459-465.
57. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al for the FinHer Study Investigators. Adjuvant docetaxel or vinoreibine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-820.
58. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-916.
59. Mann DL. Targeted cancer therapeutics: the heartbreak of success. Nat Med. 2006,12:881-882.
60. Strebhardt K, Ullrich A. Another look at imatinib mesylate. N Engl J Med. 2006;355:2481-2482.
61. Avastin [package insert]. South San Francisco, CA: Genentech, Inc; 2008.
62. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25:2420-2425.